The Brazilian National Health Surveillance Agency (Anvisa) is monitoring the latest developments around Ebola antiviral drug remdesivir, after U.S. regulators have greenlit its use in experimental trials on severe Covid-19 patients. The approval for its use followed a government-backed study involving 1,063 people, which showed that remdesivir shortened recovery time by 31 percent — an average of about four days.
The Brazilian agency has contacted U.S. pharmaceutical company Gilead, which owns remdesivir. “Within the next few days, we will meet with the manufacturer to verify the interest and viability of supplying Brazil with the drug,” the agency said in a statement.
According to the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University, Covid-19 has killed over 240,000 people worldwide —including 6,329 people in Brazil.